Pelthos Therapeutics Inc.
PTHS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $85,722 | $8,071 | $7,231 | $7,033 |
| - Cash | $14,253 | $59 | $131 | $513 |
| + Debt | $3,480 | $2,305 | $2,503 | $2,186 |
| Enterprise Value | $74,949 | $10,316 | $9,603 | $8,706 |
| Revenue | $7,406 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $4,022 | $0 | $0 | $0 |
| % Margin | 54.3% | – | – | – |
| EBITDA | -$14,215 | -$3,230 | -$1,834 | -$1,819 |
| % Margin | -191.9% | – | – | – |
| Net Income | -$16,238 | -$3,449 | -$1,968 | -$1,927 |
| % Margin | -219.3% | – | – | – |
| EPS Diluted | -25.35 | -5.38 | -3.2 | -3.23 |
| % Growth | -371.2% | -68.1% | 0.9% | – |
| Operating Cash Flow | -$15,259 | -$447 | -$632 | -$670 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$15,259 | -$447 | -$632 | -$670 |